Molotinib Instructions

1. Indications

Molotinib, trade nameOjjaara, is an innovative drug used to treat myelofibrosis. Particularly indicated for patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. It plays a therapeutic role by inhibiting specific kinase activity and interfering with abnormal cell signaling associated with disease.

2. Usage and dosage

Dosage: The recommended dose of molotinib is 200 mg daily. However, in patients with severe hepatic impairment (Child-Pugh class C), the recommended starting dose should be reduced to 150 mg daily. The medication is provided in tablet form, each tablet containing a corresponding amount of medication.

Usage: Molotinib should be taken orally, with or without food. It is important that patients swallow the tablets whole and avoid cutting, crushing or chewing to ensure proper release and absorption of the medication in the intestines. If you occasionally miss a dose, you should continue taking it as originally planned the next day. It is not recommended to double the dose.

3. Side effects

Molotinib may cause some side effects during treatment. Common side effects include low platelets, bleeding, bacterial infections, fatigue, dizziness, diarrhea and nausea. These side effects are usually mild to moderate and can be relieved with appropriate medical management in most cases. However, if serious or persistent side effects occur, they should be reported to your doctor immediately.

In addition, molotinib may interact with other drugs, especially when used concurrently with organic anion transporting polypeptide (OATP) 1B1/B3 inhibitors, which may increase the plasma concentration of molotinib, thus increasing the risk of adverse reactions. Therefore, before using molotinib, patients should inform their doctor about all medications they are taking to avoid potential interactions.

4. Precautions

Risk of infection: Patients with active infection should be carefully evaluated before initiating molotinib and monitored for signs and symptoms of infection.

Liver function monitoring: Because molotinib is metabolized in the liver, liver function should be monitored regularly, particularly before initiation of and during treatment.

Special Populations: The safety of molotinib in pregnant and breastfeeding women has not been established, so a doctor should be consulted before use. In addition, safety and effectiveness in children and adolescent patients have not been established.

Other monitoring: During treatment, the patient's complete blood count (CBC) and other related indicators should also be regularly monitored to ensure the effectiveness and safety of the drug.

5. Storage

Molotinib should be stored20°C to 25°C (68°F to 77°F), with an allowed temperature fluctuation range of 15°C to 30°C (59°F to 86°F). Medications should be stored in their original bottles to avoid moisture, and the caps should be tightly capped after each opening. To maintain the stability of the drug, it is not recommended to expose the drug to direct sunlight or high temperature.

In summary, as a new drug for the treatment of myelofibrosis, molotinib’s unique mechanism brings new treatment options to patients. When using, patients should strictly follow the doctor's instructions and pay attention to the usage and dosage of the drug, possible side effects, and related precautions and storage requirements to ensure the safety and effectiveness of the drug.